Abstract |
Results of adjuvant hormone therapy with Tamoxifen, an antioestrogenic substance, have been discussed. 82 patients in 2 groups who were diagnosed with metastatic mammary carcinoma received Tamoxifen (ICI) and Tamoxifen (Ebewe) orally in a dosage of 20 to 40 mg/day. 43% of the patients in group A ( Tamoxifen, ICI) experienced complete or partial remission of the metastases. In group B ( Tamoxifen, Ebewe), this result was achieved in 54% of cases. The better results were due to the fact that the disease was not so advanced in the group B patients and they were also longer in the menopause. Thus in terms of efficacy, the preparations are identical. Severe side effects due to the therapy were not observed.
|
Authors | T Pienkowski, A Palucka-Bartoszewicz, F Pienkowska, J Zborzil, J Schneider |
Journal | Wiener medizinische Wochenschrift (1946)
(Wien Med Wochenschr)
Vol. 141
Issue 13
Pg. 294, 297-300
( 1991)
ISSN: 0043-5341 [Print] Austria |
Vernacular Title | Behandlung des metastasierenden Mamma-karzinoms unter Anwendung von Antiöstrogenen. |
PMID | 1926878
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Breast Neoplasms
(drug therapy, pathology)
- Female
- Humans
- Middle Aged
- Remission Induction
- Tamoxifen
(adverse effects, therapeutic use)
|